Gamida Cell Ltd (NASDAQ:GMDA) Given Average Rating of “Buy” by Brokerages

Gamida Cell Ltd (NASDAQ:GMDA) has been given an average recommendation of “Buy” by the seven brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $19.00.

GMDA has been the topic of several recent analyst reports. Oppenheimer set a $18.00 price target on shares of Gamida Cell and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research lowered shares of Gamida Cell from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. Finally, ValuEngine upgraded shares of Gamida Cell from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

Institutional investors have recently made changes to their positions in the business. Bank Hapoalim BM acquired a new stake in Gamida Cell in the second quarter valued at $195,000. Edmond DE Rothschild Holding S.A. acquired a new stake in Gamida Cell in the first quarter valued at $53,000. Norges Bank acquired a new stake in Gamida Cell in the fourth quarter valued at $88,000. FMR LLC acquired a new stake in Gamida Cell in the fourth quarter valued at $1,243,000. Finally, Millennium Management LLC acquired a new stake in Gamida Cell in the fourth quarter valued at $210,000. Institutional investors own 1.72% of the company’s stock.

NASDAQ:GMDA traded down $0.09 during mid-day trading on Friday, hitting $3.60. The stock had a trading volume of 18,612 shares, compared to its average volume of 21,861. The firm’s 50-day simple moving average is $4.65. The company has a market capitalization of $90.55 million and a P/E ratio of -0.34. Gamida Cell has a twelve month low of $3.52 and a twelve month high of $15.41. The company has a quick ratio of 6.52, a current ratio of 6.52 and a debt-to-equity ratio of 0.36.

Gamida Cell (NASDAQ:GMDA) last issued its earnings results on Tuesday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.25). As a group, equities analysts anticipate that Gamida Cell will post -1.95 EPS for the current fiscal year.

About Gamida Cell

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

See Also: Is the QQQ ETF safe?

Analyst Recommendations for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.